Search results for "slas europe 2018"

Vireo™ promises to enable high-speed, AI-driven live-cell imaging for drug discovery

Provides helper phage function in packaging a common phage display phagemid. Infection of bacteria via pIII.

Explore the products you’ve told us are advancing science and research in Life Sciences

Elevate your 3D research with Gri3D ® , the ready-to-use microwell plate designed for highthroughput, reproducible organoid culture. Based on a standard 96-microtiter plate, each well contains an ultra-dense U-bottom microwell array patterned in a cell-repellent hydrogel. Organoids are robustly generated in microwells, where they grow in suspension-like conditions and are located in the same imaging plane. A pipetting port on…

Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan

Data shows that iota-carrageenan might be an effective virus blocker irrespective of present and possible future SARS-CoV-2 mutations

Dr. Stanley F. Lo, DABCC, FADLM, has been elected to serve on the ADLM board of directors as president-elect starting in August 2025

Unparalleled performance on a personalized platform

Starlab is organising a series of international events to promote sustainability in laboratories

The Mag-Bind cfDNA LSP Kit was showcased at SLAS2025 International Conference & Exhibition in San Diego, California

Dr. Timothy Maul discusses the challenges of patient blood management during ECMO and the impact of accurate POC devices for clinical decision making

Droplet Digital PCR System, includes droplet generator, droplet reader, laptop computer, software, associated component consumables, for EvaGreen or probe-based digital PCR applications

Revvity is set to unveil its new Phenologic.AI software at SLAS2025 International Conference & Exhibition in San Diego, California

Five-Mode Microplate Reader with Automatic NFC Filter Identification and Western Blot Capability

Allows improved identification of partial RhD types, including DOL, DCS, DMH, DHK/DAU-4, weak D types 1 and 2 as well as DMHi.

Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC